Charles Bonnet Syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors.
Visual hallucinations are a common and often distressing consequence of vision loss, particularly in age-related macular degeneration. Charles Bonnet Syndrome (CBS) is defined by the triad of complex visual hallucinations, ocular pathology causing visual deterioration and preserved cognitive status. So far, although this condition is frequent, no established treatment for CBS has been stated. We report here the case of a 78-year-old woman, who came in our hospital because of a 4-week long mild depressive symptomatology. For 1 year she experienced daily sudden, unexpected, vivid and elaborate hallucinations. Insight was completely present, so the patient stated that the hallucinations were unreal and that the faces, geometrical figures and animals she saw every day were possibly due to her vision loss. The Mini Mental State Examination, digit span and verbal fluency were administered and no cognitive impairment was reported. The visual acuity was hand motion. After 4 days of treatment with venlafaxine the hallucinations completely disappeared. This is the first case to show that selective serotonin (and noradrenalin) reuptake inhibitors may be an effective and well-tolerated treatment for visual hallucinations associated with vision loss, and it adds to evidence implicating serotonergic pathways in the pathogenesis of visual hallucinations.
Lang
Undine E
UE
Department of Psychiatry, University of Dresden, Dresden, Germany. undine.lang@gmx.de
Stogowski
Dariusz
D
Schulze
Doreen
D
Domula
Markus
M
Schmidt
Eckart
E
Gallinat
Jüergen
J
Tugtekin
Sems Malte
SM
Felber
Werner
W
D000368:Aged; D003071:Cognition; D003511:Cyclohexanols / Q000627:therapeutic use*; D005128:Eye Diseases / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D005260:Female; D006212:Hallucinations / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013577:Syndrome; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride; D014786:Vision Disorders / Q000150:complications* / Q000188:drug therapy / Q000209:etiology / Q000523:psychology
D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride